AI Image
Moderna, Merck shares fall on eagerly anticipated cancer vaccine results
BioPharma Dive • • general
Key Points:
- Moderna and Merck's cancer vaccine, intismeran autogene, combined with Keytruda, significantly reduced the risk of advanced melanoma recurrence or death by 42% compared to Keytruda alone, meeting expectations in a late-stage trial.
- The combination therapy also lowered the risk of cancer spreading to distant organs by 38%, with manageable side effects such as fever and injection-site pain leading to slightly higher treatment discontinuation rates.
- Despite meeting clinical goals, the results were slightly below some investor expectations, causing Moderna’s stock to drop nearly 25%, though analysts maintain the data represents a meaningful advance in melanoma treatment.
- Intismeran uses mRNA technology to train the immune system to target up to 34 patient-specific tumor neoantigens, marking a promising step in individualized cancer vaccines after decades of research challenges.
- Ongoing trials are exploring the vaccine’s effectiveness in other cancers like lung, bladder, and kidney, but its broader impact remains uncertain following mixed results from similar personalized vaccine efforts by other companies.
